| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ab499b635f68e4527a4cd823e3f820c8 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2760-18132 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-768
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-17 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K-
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A01N63-00 |
| filingDate |
2004-03-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bbed27850fb77fdfc4c5a935b6763bdd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9cecb4d4f5122f5788c39bbef7e27ec3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0330e0b8f69656ad0743fcd0000b0ffc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dfe84dba7d5a8d97f6cfc9d194c8d784
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_51354698e60122a1411b1a3a32bb6b67 |
| publicationDate |
2008-04-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
NZ-543058-A |
| titleOfInvention |
Newcastle disease virus administration |
| abstract |
Disclosed is the use of an effective amount of a Newcastle disease virus in the manufacture of a pharmaceutical preparation for treating a mammalian subject having a tumor, wherein the pharmaceutical preparation is adapted to be administered to the subject in one or more cycles; wherein at least one cycle of the pharmaceutical preparation includes one or more initial doses of from 1.8 x 1010 PFU to 4.8 x 1010 PFU of the virus per square meter of patient surface area and wherein the pharmaceutical preparation includes at least one or more subsequent doses of from 2.4 x 1010 PFU to 1.2 x 1011 PFU of the virus per square meter of patient surface area; wherein the one or more initial doses are desensitization doses and the subsequent doses are escalated doses, the amount of the virus in each escalated dose being higher than the amount of virus in each desensitization dose. |
| priorityDate |
2003-03-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |